Pub Date : 2026-01-16DOI: 10.1007/s00259-025-07740-y
Vincent Bourbonne,P Lovinfosse,M Geier,R Le Pennec,R Abgral,K Pluchon,J N Choplain,B Duysinx,F Lallemand,Arnaud Uguen,R Hustinx,R Magwenzi,M Hatt,O Pradier,F Lucia
PURPOSE/OBJECTIVE(S)Accurate detection of occult lymph node metastasis (OLNM) in patients with localized non-small cell lung cancer (NSCLC) remains a clinical challenge. This study aimed to develop and validate a radiomics-based predictive model for OLNM.MATERIALS/METHODSA radiomics model (ModelPET) and a model (ModelCombined) combining radiomics and clinical features were developed using a retrospective monocentric cohort of localized NSCLC patients treated with surgery (Cohort A) and tested on an external cohort (Cohort B) of 112 localized NSCLC patients also treated with surgery (publicly available Radiogenomics cohort). The model was further assessed in an independent cohort of 488 patients with localized NSCLC who underwent definitive stereotactic body radiotherapy (SBRT) (Cohort C) using regional relapse free survival (RRFS) as a surrogate for OLNM. Radiomic features were extracted from pre-treatment FDG PET and combined to predict OLNM using a multilayer perceptron approach.RESULTSIn the training cohort, the ModelPET and ModelCombined achieved AUCs of 0.92/0.99 and balanced accuracies (Bacc) of 80.0%/85.3%, respectively. In the Cohort B, the ModelPET and ModelCombined resulted in AUCs of 0.73/0.67 and Baccs of 71.2%/51.7%, respectively. In the Cohort C, the predicted OLNM risk based on ModelPET was significantly associated with worse RFFS (HR 1.60 95% CI 1.03-2.48, p = 0.04). The ModelCombined was not associated with survival outcomes (p > 0.05).CONCLUSIONThis study presents a radiomics-based predictive model for OLNM in localized NSCLC, validated across several retrospective independent cohorts. Subject to a prospective evaluation, the model could be used to refine clinical decision-making.
目的/目的(S)准确检测局限性非小细胞肺癌（NSCLC）患者的隐匿性淋巴结转移（OLNM）仍然是一个临床挑战。本研究旨在开发和验证基于放射组学的OLNM预测模型。材料/方法：采用手术治疗的局部NSCLC患者的回顾性单中心队列（队列a）建立放射组学模型（ModelPET）和结合放射组学和临床特征的模型（ModelCombined），并在112例也接受手术治疗的局部NSCLC患者的外部队列（队列B）中进行测试（公开可用的放射基因组学队列）。该模型在488例局部NSCLC患者的独立队列中进一步进行了评估，这些患者接受了明确的立体定向放疗（SBRT）（队列C），使用区域无复发生存率（RRFS）作为OLNM的替代指标。从预处理的FDG PET中提取放射学特征，并使用多层感知器方法结合预测OLNM。结果在训练队列中，ModelPET和modelcombination的auc分别为0.92/0.99，平衡准确率（Bacc）分别为80.0%/85.3%。在队列B中，ModelPET和ModelCombined的auc分别为0.73/0.67，bacc分别为71.2%/51.7%。在队列C中，基于ModelPET预测的OLNM风险与较差的RFFS显著相关（HR 1.60 95% CI 1.03-2.48, p = 0.04）。ModelCombined与生存结果无相关性（p < 0.05）。本研究提出了一种基于放射组学的局部NSCLC OLNM预测模型，并在多个回顾性独立队列中得到验证。经过前瞻性评估，该模型可用于改进临床决策。
{"title":"Development and external validation of a FDG PET-based radiomics model predicting occult lymph node metastasis in non-small cell lung cancer patients.","authors":"Vincent Bourbonne,P Lovinfosse,M Geier,R Le Pennec,R Abgral,K Pluchon,J N Choplain,B Duysinx,F Lallemand,Arnaud Uguen,R Hustinx,R Magwenzi,M Hatt,O Pradier,F Lucia","doi":"10.1007/s00259-025-07740-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07740-y","url":null,"abstract":"PURPOSE/OBJECTIVE(S)Accurate detection of occult lymph node metastasis (OLNM) in patients with localized non-small cell lung cancer (NSCLC) remains a clinical challenge. This study aimed to develop and validate a radiomics-based predictive model for OLNM.MATERIALS/METHODSA radiomics model (ModelPET) and a model (ModelCombined) combining radiomics and clinical features were developed using a retrospective monocentric cohort of localized NSCLC patients treated with surgery (Cohort A) and tested on an external cohort (Cohort B) of 112 localized NSCLC patients also treated with surgery (publicly available Radiogenomics cohort). The model was further assessed in an independent cohort of 488 patients with localized NSCLC who underwent definitive stereotactic body radiotherapy (SBRT) (Cohort C) using regional relapse free survival (RRFS) as a surrogate for OLNM. Radiomic features were extracted from pre-treatment FDG PET and combined to predict OLNM using a multilayer perceptron approach.RESULTSIn the training cohort, the ModelPET and ModelCombined achieved AUCs of 0.92/0.99 and balanced accuracies (Bacc) of 80.0%/85.3%, respectively. In the Cohort B, the ModelPET and ModelCombined resulted in AUCs of 0.73/0.67 and Baccs of 71.2%/51.7%, respectively. In the Cohort C, the predicted OLNM risk based on ModelPET was significantly associated with worse RFFS (HR 1.60 95% CI 1.03-2.48, p = 0.04). The ModelCombined was not associated with survival outcomes (p > 0.05).CONCLUSIONThis study presents a radiomics-based predictive model for OLNM in localized NSCLC, validated across several retrospective independent cohorts. Subject to a prospective evaluation, the model could be used to refine clinical decision-making.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"63 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSETo evaluate the prognostic value of baseline [68Ga]Ga-DOTA-NOC PET/CT-derived volumetric and uptake parameters in paediatric neuroblastoma patients.METHODSSixty‑five newly diagnosed patients underwent baseline [68Ga]Ga‑DOTA‑NOC PET/CT. Primary‑tumour and whole‑body metrics were measured: SUVmax, SUVmean, SUVpeak (standardized uptake values), Gross Tumour Volume (GTV), and Total Lesion NOC (TL‑NOC). Cox regression evaluated predictors of progression‑free survival (PFS) and overall survival (OS).RESULTSOver a median 30‑month follow‑up (range 10-51), 20 progressed and 11 died. High‑risk cases (n = 38) had higher uptake and volumes than non high‑risk (n = 27): primary‑tumour and whole‑body SUVmax (p = 0.006 and 0.001); primary‑tumour SUVpeak (p = 0.013); whole‑body TL‑NOC(p = 0.001) and GTV (p = 0.016). On multivariable Cox analysis, primary‑tumour SUVmax (HR = 1.07, 95% CI: 1.02-1.12, P = 0.005) and SUVpeak (HR = 1.06, 95% CI: 1.01-1.11, P = 0.025), as well as whole‑body TL‑NOC (per 100 SUV × cm3; HR = 1.03, 95% CI: 1.01-1.05, P = 0.013), remained independently associated with PFS, whereas whole‑body TL‑NOC (per 100 SUV × cm3; HR = 1.07, 95% CI: 1.03-1.10, P = 0.001), whole‑body GTV (per 50 cm3; HR = 1.08, 95% CI: 1.01-1.16, P = 0.028) and primary‑tumour TL‑NOC (per 100 SUV × cm3; HR = 1.08, 95% CI: 1.01-1.15, P = 0.026) were independent predictors of OS. A whole‑body TL‑NOC > 1357.05 SUV × cm3 identified patients with significantly worse PFS and OS.CONCLUSIONParameters derived from [68Ga]Ga‑DOTA‑NOC PET/CT, especially whole‑body TL‑NOC, are independent predictors of PFS and OS in neuroblastoma, supporting their use for risk stratification.
{"title":"Prognostic value of baseline [68Ga]Ga‑DOTA‑NOC PET/CT in paediatric neuroblastoma.","authors":"Qinfeng Xu,Yueran Chen,Jieping Song,Wanhua Guo,Guoqiang Shao","doi":"10.1007/s00259-025-07745-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07745-7","url":null,"abstract":"PURPOSETo evaluate the prognostic value of baseline [68Ga]Ga-DOTA-NOC PET/CT-derived volumetric and uptake parameters in paediatric neuroblastoma patients.METHODSSixty‑five newly diagnosed patients underwent baseline [68Ga]Ga‑DOTA‑NOC PET/CT. Primary‑tumour and whole‑body metrics were measured: SUVmax, SUVmean, SUVpeak (standardized uptake values), Gross Tumour Volume (GTV), and Total Lesion NOC (TL‑NOC). Cox regression evaluated predictors of progression‑free survival (PFS) and overall survival (OS).RESULTSOver a median 30‑month follow‑up (range 10-51), 20 progressed and 11 died. High‑risk cases (n = 38) had higher uptake and volumes than non high‑risk (n = 27): primary‑tumour and whole‑body SUVmax (p = 0.006 and 0.001); primary‑tumour SUVpeak (p = 0.013); whole‑body TL‑NOC(p = 0.001) and GTV (p = 0.016). On multivariable Cox analysis, primary‑tumour SUVmax (HR = 1.07, 95% CI: 1.02-1.12, P = 0.005) and SUVpeak (HR = 1.06, 95% CI: 1.01-1.11, P = 0.025), as well as whole‑body TL‑NOC (per 100 SUV × cm3; HR = 1.03, 95% CI: 1.01-1.05, P = 0.013), remained independently associated with PFS, whereas whole‑body TL‑NOC (per 100 SUV × cm3; HR = 1.07, 95% CI: 1.03-1.10, P = 0.001), whole‑body GTV (per 50 cm3; HR = 1.08, 95% CI: 1.01-1.16, P = 0.028) and primary‑tumour TL‑NOC (per 100 SUV × cm3; HR = 1.08, 95% CI: 1.01-1.15, P = 0.026) were independent predictors of OS. A whole‑body TL‑NOC > 1357.05 SUV × cm3 identified patients with significantly worse PFS and OS.CONCLUSIONParameters derived from [68Ga]Ga‑DOTA‑NOC PET/CT, especially whole‑body TL‑NOC, are independent predictors of PFS and OS in neuroblastoma, supporting their use for risk stratification.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"39 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1007/s00259-025-07744-8
Gabriel T Sheikh,Sophie C Siegmund,Liam Widjaja,Sarah L Takayama Fouladgar,Astrid Delker,Jozefina Casuscelli,Lena M Unterrainer,Rudolf A Werner,Mathias J Zacherl
PURPOSE225Ac-Targeted alpha therapy is a potent and promising option for patients with metastatic castration-resistant prostate cancer (mCRPC) and failure of guideline-based therapies and 177Lu-PSMA-radioligand therapy. Unfortunately, side effects associated with TAT can significantly affect quality of life. A combination treatment regimen adding 177Lu and reducing 225Ac activities may mitigate side effects while preserving sufficient anti-tumour efficacy. We therefore evaluated different combinations [225Ac]Ac-/[177Lu]Lu-PSMA-I&T (ALCT) with regard to response and adverse events.METHODSA total of 19 consecutive patients treated with ALCT on compassionate use basis at our department were evaluated. Patients were divided into two different subgroups, depending on the 225Ac/177Lu-activity administered: group 1 (Gr1) received 4MBq and 4000MBq, group 2 (Gr2) 8 MBq and 1000MBq per therapy cycle, respectively. Laboratory (PSA, ALP, LDH, Hb, Lc, Tc, Crea) and imaging parameters on [18F]PSMA-1007-PET/CTs (TTV, SUVmax/mean) at baseline and after 2 cycles of therapy were evaluated for the total patient population as well as each therapy subgroup and statistically compared. Adverse events (xerostomia, anemia, leukopenia, thrombocytopenia, weight loss) were recorded. Response evaluation criteria in PSMA-PET/CT (RECIP 1.0) was used for response evaluation.RESULTSAccording to the RECIP composite classification, 4 of 10 (40%) of patients from Gr1 and 5 of 9 (56%) from Gr2 showed a partial response, while 4/10 (40%) and 2/9 (22%) of patients from Gr1 and 2, respectively, showed progressive disease. After 2 cycles of ALCT the following adverse events newly developed or worsened by at least one grade: anemia in 2/10 (20%) patients from Gr1 and 3/9 (33%) patients from Gr2; thrombocytopenia in 1/10 (10%) patients from Gr1; leukopenia in 4/10 (40%) from Gr1 and 2/9 (22%) from Gr2; weight loss in 1/10 (10%) from Gr1 and 2/9 (22%) from Gr2 and xerostomia in 3/10 (30%) from Gr1 and 5/9 (56%) from Gr2. There was no significant difference between the two groups in respect to absolute values after therapy or pre- and post-therapy difference in any of the laboratory or imaging parameters evaluated.CONCLUSIONAlthough no significant difference in response or adverse events could be found between the two treatment groups, ALCT with higher 225Ac-activities seems to favor a better outcome, albeit at the cost of a higher risk of xerostomia. ALCT with lower 225Ac activities may be a good choice when conserving salivary gland function and therefore quality of life is of higher concern, but renders more careful monitoring of blood values necessary.
{"title":"Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [225Ac]Ac/[177Lu]Lu-PSMA-therapy.","authors":"Gabriel T Sheikh,Sophie C Siegmund,Liam Widjaja,Sarah L Takayama Fouladgar,Astrid Delker,Jozefina Casuscelli,Lena M Unterrainer,Rudolf A Werner,Mathias J Zacherl","doi":"10.1007/s00259-025-07744-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07744-8","url":null,"abstract":"PURPOSE225Ac-Targeted alpha therapy is a potent and promising option for patients with metastatic castration-resistant prostate cancer (mCRPC) and failure of guideline-based therapies and 177Lu-PSMA-radioligand therapy. Unfortunately, side effects associated with TAT can significantly affect quality of life. A combination treatment regimen adding 177Lu and reducing 225Ac activities may mitigate side effects while preserving sufficient anti-tumour efficacy. We therefore evaluated different combinations [225Ac]Ac-/[177Lu]Lu-PSMA-I&T (ALCT) with regard to response and adverse events.METHODSA total of 19 consecutive patients treated with ALCT on compassionate use basis at our department were evaluated. Patients were divided into two different subgroups, depending on the 225Ac/177Lu-activity administered: group 1 (Gr1) received 4MBq and 4000MBq, group 2 (Gr2) 8 MBq and 1000MBq per therapy cycle, respectively. Laboratory (PSA, ALP, LDH, Hb, Lc, Tc, Crea) and imaging parameters on [18F]PSMA-1007-PET/CTs (TTV, SUVmax/mean) at baseline and after 2 cycles of therapy were evaluated for the total patient population as well as each therapy subgroup and statistically compared. Adverse events (xerostomia, anemia, leukopenia, thrombocytopenia, weight loss) were recorded. Response evaluation criteria in PSMA-PET/CT (RECIP 1.0) was used for response evaluation.RESULTSAccording to the RECIP composite classification, 4 of 10 (40%) of patients from Gr1 and 5 of 9 (56%) from Gr2 showed a partial response, while 4/10 (40%) and 2/9 (22%) of patients from Gr1 and 2, respectively, showed progressive disease. After 2 cycles of ALCT the following adverse events newly developed or worsened by at least one grade: anemia in 2/10 (20%) patients from Gr1 and 3/9 (33%) patients from Gr2; thrombocytopenia in 1/10 (10%) patients from Gr1; leukopenia in 4/10 (40%) from Gr1 and 2/9 (22%) from Gr2; weight loss in 1/10 (10%) from Gr1 and 2/9 (22%) from Gr2 and xerostomia in 3/10 (30%) from Gr1 and 5/9 (56%) from Gr2. There was no significant difference between the two groups in respect to absolute values after therapy or pre- and post-therapy difference in any of the laboratory or imaging parameters evaluated.CONCLUSIONAlthough no significant difference in response or adverse events could be found between the two treatment groups, ALCT with higher 225Ac-activities seems to favor a better outcome, albeit at the cost of a higher risk of xerostomia. ALCT with lower 225Ac activities may be a good choice when conserving salivary gland function and therefore quality of life is of higher concern, but renders more careful monitoring of blood values necessary.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"52 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145961411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSEWe previously proposed that a probability-based sympathetic 123I-meta-iodobenzylguanidine (mIBG) index (SMILe) could distinguish the presence or absence of Lewy body disease (LBD) based on findings at a single center. However, whether the model would be useful in the real world remained uncertain. Therefore, we updated and evaluated its performance at five Japanese and three European institutions.METHODSWe compared data from 967 patients with suspected LBD with 62 controls from a normal database (NDB). Of 815 patients with guideline-based diagnoses, 483 had LBD (Parkinson disease [PD] or dementia with Lewy bodies [DLB]) and 332 did not have LBD. Heart-to-mediastinum (H/M) ratios were standardized using a phantom-based method. Logistic regression models included early and late H/M ratios, age, sex, and comorbidities. We assessed diagnostic performance using ROC analysis and cross-validation.RESULTSThe updated model discriminated LBD from other diseases (AUC for early and late H/M, 0.880 0.899, respectively). Age correction of H/M ratios based on the NDB did not improve accuracy. Median early H/M ratios [SMILe probability] were 3.09 [12.8%] for NDB, 2.57 [37.5%] for Alzheimer disease, 1.76 [84.7%] for PD, and 1.62 [89.0%] for DLB, with significantly lower H/M ratios and higher probabilities in PD and DLB compared with controls (p < 0.0001). Late-phase imaging added value mainly in intermediate borderline (30%-70%) situations. Coronary artery disease attenuated the diagnostic performance of SMILe.CONCLUSIONThe probability-based 123I-mIBG model reliably differentiated LBD from other diseases. Standardization among sites supports global applicability and reflects real-world clinical practice.
{"title":"Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine.","authors":"Kenichi Nakajima,Junji Komatsu,Takeshi Matsumura,Satoshi Orimo,Mitsuhiro Yoshita,Viviana Frantellizzi,Maria Silvia De Feo,Gemma Greenfinch,Alan Thomas,Roberta Assante,Wanda Acampa,Naoki Shirasaki,Kunihiko Yokoyama,Hiroshi Wakabayashi,Moeko Noguchi-Shinohara,Kenjiro Ono,Seigo Kinuya","doi":"10.1007/s00259-025-07706-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07706-0","url":null,"abstract":"PURPOSEWe previously proposed that a probability-based sympathetic 123I-meta-iodobenzylguanidine (mIBG) index (SMILe) could distinguish the presence or absence of Lewy body disease (LBD) based on findings at a single center. However, whether the model would be useful in the real world remained uncertain. Therefore, we updated and evaluated its performance at five Japanese and three European institutions.METHODSWe compared data from 967 patients with suspected LBD with 62 controls from a normal database (NDB). Of 815 patients with guideline-based diagnoses, 483 had LBD (Parkinson disease [PD] or dementia with Lewy bodies [DLB]) and 332 did not have LBD. Heart-to-mediastinum (H/M) ratios were standardized using a phantom-based method. Logistic regression models included early and late H/M ratios, age, sex, and comorbidities. We assessed diagnostic performance using ROC analysis and cross-validation.RESULTSThe updated model discriminated LBD from other diseases (AUC for early and late H/M, 0.880 0.899, respectively). Age correction of H/M ratios based on the NDB did not improve accuracy. Median early H/M ratios [SMILe probability] were 3.09 [12.8%] for NDB, 2.57 [37.5%] for Alzheimer disease, 1.76 [84.7%] for PD, and 1.62 [89.0%] for DLB, with significantly lower H/M ratios and higher probabilities in PD and DLB compared with controls (p < 0.0001). Late-phase imaging added value mainly in intermediate borderline (30%-70%) situations. Coronary artery disease attenuated the diagnostic performance of SMILe.CONCLUSIONThe probability-based 123I-mIBG model reliably differentiated LBD from other diseases. Standardization among sites supports global applicability and reflects real-world clinical practice.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145961408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1007/s00259-025-07742-w
A El Ghalbouni,T J Snijders,N Tolboom,A J A T Braat
{"title":"Near complete response recurrent glioblastoma after treatment with [131I]-Iodofalan.","authors":"A El Ghalbouni,T J Snijders,N Tolboom,A J A T Braat","doi":"10.1007/s00259-025-07742-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07742-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"4 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145961410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1007/s00259-025-07712-2
Magdalena Sophie Späth, Helmut Dittmann, Richard Spallek, Eduardo Calderón, Jonas Mück, Andreas Brendlin, Steffen Rausch, Christian la Fougère, Nils F. Trautwein
{"title":"PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT)","authors":"Magdalena Sophie Späth, Helmut Dittmann, Richard Spallek, Eduardo Calderón, Jonas Mück, Andreas Brendlin, Steffen Rausch, Christian la Fougère, Nils F. Trautwein","doi":"10.1007/s00259-025-07712-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07712-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"46 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s00259-025-07736-8
Otto M Henriksen,Oriol P Calvo,Frederik J Bruun,Marie Bruun,Steen G Hasselbalch,Kristian S Frederiksen,Adam E Hansen,Ian Law,Ulrich Lindberg
PURPOSETo assess the quantitative and visual concordance of multiple post-labelling delay (multi-PLD) arterial spin labelling (ASL) MRI cerebral blood flow (CBF) measurements and [18F]-fluoro-deoxyglucose (FDG) PET in a mixed memory clinic population.METHODSHybrid [18F]FDG PET/MRI including multi-PLD pseudo continuous ASL from 96 memory clinic patients and 38 elderly controls were analysed along with ASL data from 12 healthy young volunteers. ASL image interpretability, concordance with [18F]FDG PET, and value of Z-score maps were rated visually. Regional associations of CBF with [18F]FDG uptake ratio (SUVr) were investigated by univariate regression and mixed linear models. Also influences of age, disease stage and vascular pathology on ASL interpretability and concordance, and whole cortex spatial coefficient of variation (sCOV) were analysed.RESULTSASL CBF maps were non-comparable to [18F]FDG PET, i.e. uninterpretable or discordant, in 53% of patients, 37% of elderly controls, and 8% of young controls. Only 14% of patient ASL MRI scans were concordant with [18F]FDG PET. Z-score maps were mainly of value in partially concordant scans. Increasing sCOV was strongly associated both with disease severity and with decreasing ASL interpretability and concordance, and allowed for identification of uninterpretable scans with 95% sensitivity and 90% specificity. Whole cortex CBF and [18F]FDG SUVr values showed similar distribution across groups, but low to moderate regional associations.CONCLUSIONSMulti-PLD ASL provided quantitative CBF measurements correlating with disease severity, but poor image quality and low regional concordance in head-to-head comparison with [18F]FDG PET imaging restricts the clinical use in memory clinic patients.
{"title":"Simultaneous multiple post-labelling delay ASL MRI and [18F]FDG PET in a mixed memory clinic population and healthy controls.","authors":"Otto M Henriksen,Oriol P Calvo,Frederik J Bruun,Marie Bruun,Steen G Hasselbalch,Kristian S Frederiksen,Adam E Hansen,Ian Law,Ulrich Lindberg","doi":"10.1007/s00259-025-07736-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07736-8","url":null,"abstract":"PURPOSETo assess the quantitative and visual concordance of multiple post-labelling delay (multi-PLD) arterial spin labelling (ASL) MRI cerebral blood flow (CBF) measurements and [18F]-fluoro-deoxyglucose (FDG) PET in a mixed memory clinic population.METHODSHybrid [18F]FDG PET/MRI including multi-PLD pseudo continuous ASL from 96 memory clinic patients and 38 elderly controls were analysed along with ASL data from 12 healthy young volunteers. ASL image interpretability, concordance with [18F]FDG PET, and value of Z-score maps were rated visually. Regional associations of CBF with [18F]FDG uptake ratio (SUVr) were investigated by univariate regression and mixed linear models. Also influences of age, disease stage and vascular pathology on ASL interpretability and concordance, and whole cortex spatial coefficient of variation (sCOV) were analysed.RESULTSASL CBF maps were non-comparable to [18F]FDG PET, i.e. uninterpretable or discordant, in 53% of patients, 37% of elderly controls, and 8% of young controls. Only 14% of patient ASL MRI scans were concordant with [18F]FDG PET. Z-score maps were mainly of value in partially concordant scans. Increasing sCOV was strongly associated both with disease severity and with decreasing ASL interpretability and concordance, and allowed for identification of uninterpretable scans with 95% sensitivity and 90% specificity. Whole cortex CBF and [18F]FDG SUVr values showed similar distribution across groups, but low to moderate regional associations.CONCLUSIONSMulti-PLD ASL provided quantitative CBF measurements correlating with disease severity, but poor image quality and low regional concordance in head-to-head comparison with [18F]FDG PET imaging restricts the clinical use in memory clinic patients.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s00259-025-07758-2
Luigi Mansi
{"title":"Kalevi Kairemo. Prostate cancer from a nuclear oncology perspective. A personal journey. Springer Nature Switzerland AG 2025, ISBN: 978-3-031-90336-6","authors":"Luigi Mansi","doi":"10.1007/s00259-025-07758-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07758-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"9 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-10DOI: 10.1007/s00259-025-07722-0
Phyo H. Khaing, Mark G. MacAskill, Jianfei Xiao, Shichao Liu, Zhuqin Gu, Xiaohiu Sun, Tao Xu, Norman Koglin, Andrew W. Stephens, David E. Newby, Yihui Guan, Holly McErlain, Andrew Sutherland, Gilles D. Tamagnan, Fang Xie, Adriana Alexandre S. Tavares
Purpose The 18 kDa translocator protein (TSPO) has been a central molecular target for imaging inflammation in the preclinical and clinical research settings across a plethora of applications, including neuroinflammation, cardiovascular inflammation and cancer. Recently, we reported the development of [ 18 F]LW223 as a third-generation TSPO positron emission tomography (PET) radiotracer with binding to human TSPO independent of the rs6971 genetic polymorphism. This study reports the first whole-body human analysis, including biodistribution and dosimetry calculations, following intravenous administration of [ 18 F]LW223. Methods Whole-body PET images were acquired over 250 min after intravenous bolus injection of 184.3 ± 20.2 MBq of [ 18 F]LW223 in healthy adult human volunteers. Volumes of interest (VOIs) in different source organs were manually delineated by three independent observers, then time-activity curves were generated for residency times calculations for subsequent quantification of radiation equivalent and effective doses using OLINDA/EXM 2.2 software. Results The radiotracer biodistribution in humans recapitulated known TSPO expression in various tissues. The main elimination route was found to be hepatobiliary, and the critical organ was the intestine. The cumulated radioactivity excreted by the kidneys was < 10% over the measurement period and no bone uptake suggestive of in vivo defluorination was observed in any of the study subjects. The effective dose ranged between 11.8 ± 0.9 and 12.5 ± 0.9 µSv/MBq. Inter-observer VOI variability had no impact on estimated organ and whole-body effective doses. Conclusion [ 18 F]LW223 is predominantly excreted by the hepatobiliary route with no evidence of in vivo defluorination but demonstrates marked uptake into tissues with known TSPO expression. It complies with radiation limits and guidelines recommended by regulatory authorities and is in line with previously reported [ 18 F]-labelled radiotracers, such as [ 18 F]fluorodeoxyglucose. [ 18 F]LW223 is suitable for translation into human clinical studies.
{"title":"First human whole-body biodistribution and dosimetry analysis of [18F]LW223, a novel TSPO PET radiotracer","authors":"Phyo H. Khaing, Mark G. MacAskill, Jianfei Xiao, Shichao Liu, Zhuqin Gu, Xiaohiu Sun, Tao Xu, Norman Koglin, Andrew W. Stephens, David E. Newby, Yihui Guan, Holly McErlain, Andrew Sutherland, Gilles D. Tamagnan, Fang Xie, Adriana Alexandre S. Tavares","doi":"10.1007/s00259-025-07722-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07722-0","url":null,"abstract":"Purpose The 18 kDa translocator protein (TSPO) has been a central molecular target for imaging inflammation in the preclinical and clinical research settings across a plethora of applications, including neuroinflammation, cardiovascular inflammation and cancer. Recently, we reported the development of [ <jats:sup>18</jats:sup> F]LW223 as a third-generation TSPO positron emission tomography (PET) radiotracer with binding to human TSPO independent of the rs6971 genetic polymorphism. This study reports the first whole-body human analysis, including biodistribution and dosimetry calculations, following intravenous administration of [ <jats:sup>18</jats:sup> F]LW223. Methods Whole-body PET images were acquired over 250 min after intravenous bolus injection of 184.3 ± 20.2 MBq of [ <jats:sup>18</jats:sup> F]LW223 in healthy adult human volunteers. Volumes of interest (VOIs) in different source organs were manually delineated by three independent observers, then time-activity curves were generated for residency times calculations for subsequent quantification of radiation equivalent and effective doses using OLINDA/EXM 2.2 software. Results The radiotracer biodistribution in humans recapitulated known TSPO expression in various tissues. The main elimination route was found to be hepatobiliary, and the critical organ was the intestine. The cumulated radioactivity excreted by the kidneys was < 10% over the measurement period and no bone uptake suggestive of in vivo defluorination was observed in any of the study subjects. The effective dose ranged between 11.8 ± 0.9 and 12.5 ± 0.9 µSv/MBq. Inter-observer VOI variability had no impact on estimated organ and whole-body effective doses. Conclusion [ <jats:sup>18</jats:sup> F]LW223 is predominantly excreted by the hepatobiliary route with no evidence of in vivo defluorination but demonstrates marked uptake into tissues with known TSPO expression. It complies with radiation limits and guidelines recommended by regulatory authorities and is in line with previously reported [ <jats:sup>18</jats:sup> F]-labelled radiotracers, such as [ <jats:sup>18</jats:sup> F]fluorodeoxyglucose. [ <jats:sup>18</jats:sup> F]LW223 is suitable for translation into human clinical studies.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"13 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The predictive value of 18F-FAPI PET/CT and voxel-based tumor absorbed dose for the response and clinical outcome of unresectable hepatocellular carcinoma patients treated with Yttrium-90 resin microsphere selective internal radiation therapy","authors":"Huanyu Gong, Yong Cheng, Qiang Li, Yulong Liu, Jingjie Shang, Yingxin Li, Lu Kuang, Xueying Ling, Changjing Zuo, Lu Wang, Jian Gong, Hao Xu","doi":"10.1007/s00259-025-07717-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07717-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"363 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：